Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy

MARKETS LIVE: US stock futures edge lower as investors await inflation data

MARKETS LIVE: Wall Street closes mixed as cooling inflation lifts Nasdaq

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

A rare disorder’s median survival is 6–9 years. Tiziana seeks FDA rare-disease designation for its nasal drug.

Tiziana Life Sciences doses first ALS patients in Phase 2a Foralumab trial

Tiziana doses first three patients in ALS trial of nasal antibody foralumab

Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab

Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical Trial

Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial

Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab

Tiziana Completes Phase 2a MS Trial, Topline Data Due In October

Why Is Tiziana Life Sciences Stock Gaining Thursday?

Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial

$TLSA stock is up 7% today. Here's what we see in our data.